85 results on '"Valentino, L. A."'
Search Results
2. Should anti-inhibitor coagulant complex and tranexamic acid be used concomitantly?
3. Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study
4. Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials
5. US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors
6. Safety of radiation exposure after radiosynovectomy in paediatric patients with haemophilia
7. Personalization of treatment regimens for active patients: a comparison of factor VIII and extended half-life treatment regimens: OR211
8. The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule
9. Neonatal circumcision in severe haemophilia: a survey of paediatric haematologists at United States Hemophilia Treatment Centers
10. Considerations in individualizing prophylaxis in patients with haemophilia A
11. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes
12. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects
13. Matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS): peering into the cup of Jamshid
14. Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders
15. The first recombinant FVIII produced in human cells – an update on its clinical development programme
16. Towards personalizing haemophilia care: using the Haemophilia Severity Score to assess 178 patients in a single institution
17. An ‘ice age’ concept? The use of ice in the treatment of acute haemarthrosis in haemophilia
18. Safety and pharmacokinetics of three doses of a new recombinant human Factor Vlla (LR769) in congenital hemophilia A or B patients: PO 295
19. Pharmacodynamic effects of escalating dosages of a new recombinant human Factor VIIa (LR769) in congenital hemophilia A or B patients: PO 291
20. Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A: PO 160
21. Peak FVIII levels and time spent in hemostatically effective FVIII range post-infusion correlates with improved efficacy for prophylaxis in hemophilia A: a closer look at the other end of the curve: PB 4.39–1
22. Hemostatic effect of an anti-TFPI peptide in a murine model of hemophilic joint bleeding: PB 3.58–3
23. Qualitative findings contributing to the development of a hemophilia-specific caregiver burden instrument: caregiver and health care professional insights: PB 3.38–5
24. The relationship between specific annual bleed rates and health outcomes among children with severe hemophilia A: PB 3.38–2
25. Pharmacokinetic results from a Phase I/III study of a novel recombinant single-chain factor VIII (rVIII- SingleChain) compared to octocog alfa in severe haemophilia A patients: PB 2.55–4
26. Bleeding pattern and median time interval between bleeding episodes amongst patients receiving on - demand and prophylaxis therapy: PB 2.37–2
27. Treatment of bleeding episodes in subjects with haemophilia B with the long-lasting recombinant factor IX Fc fusion protein (rFIXFc) in the phase 3 B-LONG study: PA 2.07–6
28. Clinical implications of population pharmacokinetics of rFIXFc in routine prophylaxis, control of bleeding and perioperative management for haemophilia B patients: PA 2.07–5
29. B-LONG: results from a Phase 3 study of safety, efficacy, and pharmacokinetics of long-lasting recombinant factor IX Fc Fusion Protein (rFIXFc): OC 70.1
30. Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors
31. Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII
32. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis
33. Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United States: perspectives and best practices derived from experienced treatment centres
34. The effect of cooling on coagulation and haemostasis: Should “Ice” be part of treatment of acute haemarthrosis in haemophilia?
35. Pharmacokinetics and efficacy of on-demand treatment with human-cl rhFVIII in previously treated patients with severe haemophilia A: PO-TU-170
36. Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE)
37. Consequences of intra-articular bleeding in haemophilia: science to clinical practice and beyond
38. Healthcare resource utilization among haemophilia A patients in the United States
39. Exploring the biological basis of haemophilic joint disease: experimental studies
40. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management
41. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease
42. An uncommon cause of knee haemarthrosis in an adult haemophilia patient suffering from long-term paraplegia
43. Joint protection in haemophilia
44. Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX
45. Assessment of blood-induced arthritis causes friction
46. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice
47. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy
48. Patient/caregiver-reported bleed symptoms and reasons for starting/stopping treatment with recombinant factor VIIa (rFVIIa): analysis of the dosing observational study in hemophilia (DOSE): 17P72
49. Healthcare resource utilization among hemophilia A patients with inhibitor status in the US: 14P09
50. Stability and predictability of treatment cost among non-inhibitor hemophilia patients in the US: 14P10
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.